CDTX News and Press, Cidara Therapeutics Inc. From 07/12/21

Cidara Therapeutics (CDTX) posts new analyses from multiple studies of rezafungin, the company's treatment for candidemia at the 31st European Congress of Clinical Microbiology and Infectious Diseases ((ECCMID)).Rezafungin is Cidara’s novel, once-weekly echinocandin...

Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of care Three additional presentations to highlight areas of unmet medical need...

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has...

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new anal...

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., Pr...

Crestone Joins Antimicrobials Working Group PR Newswire WASHINGTON , June 8, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug r...

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will virtually presen...

Cidara Therapeutics (CDTX): Q1 GAAP EPS of -$0.39 misses by $0.05.Revenue of $2.41M (-4.7% Y/Y) misses by $5.47M.Shares -0.5% AH.Press Release For further details see: Cidara Therapeutics EPS misses by $0.05, misses on revenue

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three...

Johnson & Johnson (NYSE: JNJ) hasn't been a major player in the vaccine market in the past, but that's changing. The healthcare giant is already marketing its COVID-19 vaccine. It's now seeking to develop a flu vaccine through a recent deal with small biotech Cidara Therapeuti...